cells are known to require ATP for all catalytic activities. However, during the purification of the enzymes, some of their native properties may be lost due to proteolytic degradation or to a resolution of their supramolecular structure (Glikin et al., 1984) .
The trypanosomal extracts, as well as the enzyme obtained after hydroxylapatite chromatography, are capable of catenating supercoiled circular DNA molecules. When this reaction was reported earlier (Riou et al., 1983) , it was stated that ATP addition was not required. The extracts contained a factor that prevented the reverse reaction of decatenation. We have now shown that trypanosomes contain a decatenating enzyme which could be a type I1 topoisomerase. Moreover, this enzyme is able to unknot P4 knotted DNA. However, the type I1 topoisomerases so far isolated depend on the presence of ATP for their activity.
We have been able to stimulate DNA cleavage by addition of mAMSA or ellipticine to the reaction mixtures. This suggests a reaction catalysed by a type I1 rather than by a type I topoisomerase. Moreover, the type I trypanosomal topoisomerase already described (Riou et al., 1983) is clearly different from the present enzyme. In particular, the sensitivity of the two enzymes to various drugs differs. The decatenating enzyme is more sensitive to ellipticines, with the exception of 2-6 diCH,-9-OH ellipticinium (Douc-Rasy et al., 1983a) , than the topoisomerase I. The inhibitory concentrations are about the same as those of a typical type I1 topoisomerase (Douc-Rasy et al., 19836) .
The study of the action of drugs on the DNA of trypanosomes can be done in vivo (Goijman et al., 1985) . The DNA breaks induced in vitro by topoisomerases under drug action might also occur in vivo and liberate linearized minicircles (Ahomadegbe et al., unpublished work) . This would be analogous to the linearization of viral DNA in infected cells (Chen et al., 1984; Yang et al., 1985) . Since trypanosomes proliferate quite rapidly in host tissues, the activity of their topoisomerase may be of a comparatively high level, as previously found in regenerating rat liver (Duguet et al., 1983) and in tumour cells (Riou et al., 1985) . The topoisomerase represents therefore, a potential target for trypanocidal agents which can either stimulate double-stranded DNA cleavage or inhibit the catalytic activity. It represents a system to select new drugs.
DNA inside bacterial cells appears to be under negative superhelical tension (Sinden et al., 1980) , and extracts from bacterial cells contain enzymes, topoisomerases, capable of altering levels of DNA superhelical tension (for reviews see Cozzarelli, 1980; Gellert, 1981) . The two best studied topoisomerases are DNA topoisomerase I (Wang, 1971) and DNA gyrase (Gellert et al., 1976~) . Both enzymes are able to remove negative superhelical tension from DNA, but only gyrase can introduce it. The following observations suggest that in vivo these two enzymes participate in maintaining the proper level of superhelical tension. First, inactivation of gyrase blocks the introduction of titratable supercoils into relaxed, circular bacteriophage lambda DNA during superinfection of a lysogen (Gellert et al., 19766; . Second, inhibition of gyrase leads to a loss of titratable supercoils from the bacterial chromosome (Drlica & Snyder, 1978) and from plasmid DNA (Pettijohn & Pfenninger, Vol. 14 1980) . Third, some mutations in topA, the gene encoding topoisomerase I, increase the level of titratable supercoiling in bacterial chromosomes and plasmids (Di Nardo et al., 1982; Pruss et al., 1982) .
Methods are available for perturbing topoisomerase activities inside living cells, and we have been using these methods to study how supercoiling/topoisomerase activity affects cell physiology. Gyrase is composed of two types of subunit, and antibiotics have been found that specifically inhibit each type of subunit. The GyrA subunit is inactivated by the antibiotics nalidixic acid, oxolinic acid, and a series of related drugs. The GyrB subunit is inactivated by the drugs coumermycin A , , novobiocin, and related compounds. The availability of drug-resistant mutations in gyrA and gyrB makes it possible to control for non-specific drug effects and allows the inhibitor studies to be interpreted in terms of effects on gyrase action. Also available are temperature-sensitive gyrase mutations. Thus shift experiments, using either antibiotics or mutations, can be performed to examine the consequences of rapidly inactivating gyrase. Inhibition of gyrase affects a wide range of cellular functions including DNA replication, transcription, recombination and plasmid stability, in addition to lowering the levels of titratable supercoils (for review see .
Supercoiling appears to be controlled, at least in part, by its own effect on gyrase gene expression. Treatments that inactivate gyrase and cause a loss of chromosomal supercoiling (Drlica & Snyder, 1978; Sinden et al., 1980; von Wright & Bridges, 1981; Steck et al., 1984) stimulate expression from the gyrase genes (Menzel & Gellert, 1983) . In vitro, the gyrase genes are expressed at higher levels from relaxed templates than from supercoiled ones (Menzel & Gellert, 1983) . These observations led Menzel & Gellert (1983) to propose a homoeostatic model for the regulation of supercoiling: conditions that lower supercoiling increase gyrase expression; higher gyrase expression in turn increases supercoiling, which then reduces gyrase expression.
Gyrase inhibitors relax DNA in the absence of topoisomerase I
As mentioned above, inhibition of gyrase in vivo leads to lower levels of titratable supercoiling (Drlica & Snyder, 1978) and superhelical tension (Sinden et al., 1980) . The availability of deletion mutations in topA allowed us to determine if relaxation induced by inhibitors of gyrase requires topoisomerase I. Chromosomal DNA relaxation, measured as described by Drlica & Snyder (1978) , occurs in AtopA mutants treated with coumermycin (50 pg/ml) or oxolinic acid (2 pg/ml) (G. Pruss, S. Manes, S. Chevalier, & K. Drlica, unpublished work). We have not yet determined if the drug-induced DNA relaxation arises from gyrase or from another topoisomerase such as topoisomerase I11 (Dean et al., 1983) .
Chromosomal DNA relaxation induced by treatment of wild-type cells with coumermycin (50 pg/ml) occurs more slowly and to a lesser extent if protein synthesis is blocked by amino acid starvation (Drlica & Snyder, 1978) . Likewise, addition of chloramphenicol (200 pg/ ml) to cells treated with coumermycin (12 pg/ml) reduces DNA relaxation to 60% of that which occurs in the presence of coumermycin alone. One trivial explanation is that inhibition of protein synthesis blocks uptake of coumermycin. However, this appears not to be the case when using chloramphenicol because inhibition of DNA synthesis by coumermycin is unaffected by chloramphenicol: the amount of inhibition created by the two drugs equals the sum of inhibition by each added separately to cells. The model of homoeostatic regulation of gyrase expression (Menzel & Gellert, 1983) leads to an interesting explanation for these observations. If coumermycin induces a gyrase-dependent DNA relaxation, then relaxation should be greater when gyrase expression is stimulated by the drug. By inhibiting protein synthesis, chloramphenicol would block production of new gyrase and thus prevent the build up of relaxing activity.
Induction of gyrase does not require chromosome relaxation
At about the same time that the homoeostatic model for gyrase expression was proposed (Menzel & Gellert, 1983) , we uncovered a puzzling phenomenon with a multiple topoisomerase mutant: treatment with oxolinic acid leads to an increase in titratable supercoiling (Manes et al., 1983) . The mutant, provisionally called DM800 oxo', was constructed by G. Pruss by transducing an oxolinic acid-resistant gyrA allele into strain DM800 (AtopA, gyrB225). DM800 0x0' is only partially resistant to oxolinic and nalidixic acids. It grows on agar plates containing 20pg of nalidixic acid/ml, but it does not grow if the nalidixic acid concentration is 50pg/ml, a concentration which allows growth of a strain carrying the gyrA 0x0' allele in an otherwise wild-type background. In addition, DNA synthesis is only partially inhibited by oxolinic acid in strain DM800 0x0' under conditions where synthesis is drastically reduced in wildtype cells but hardly affected if the wild-type strain contains the gyrA 0x0' allele.
We can now make two statements about the increase in supercoiling observed after treatment of DM800 0x0' with oxolinic acid. First, the increase in supercoiling depends on newly made proteins: when protein synthesis is blocked by chloramphenicol(200 pg/ml), oxolinic acid (5 pg/ml) fails to increase chromosomal DNA supercoiling. Second, using two-dimensional protein gel electrophoretic techniques, we find that the rate of GyrA production increases about 2-fold after treatment of cells with oxolinic acid. Although we could not resolve the gyrB225 gene product with our electrophoresis system, it is likely that the increase in gyrA expression represents an increase in the amount of gyrase present in the cell.
It appears that the oxolinic acid-induced increase in supercoiling exhibited by DM800 0x0' arises from the unusual properties of the mutant gyrase enzyme that it contains. The gyrase is induced by oxolinic acid but is still active in the presence of the drug. Thus the drug treatment increases the amount of supercoiling activity in the cell. Since the mutant lacks topoisomerase I to counterbalance the increase in gyrase activity, the net effect is an increase in supercoiling.
A similar phenomenon may occur in wild-type strains. Previously we showed that low doses of either coumermycin or oxolinic acid produce anomalous effects on titratable supercoiling: low concentrations of coumermycin (1-3 pg/ml) cause supercoiling to increase while low oxolinic acid concentrations (1-3 pg/ml), concentrations sufficient to block DNA synthesis, cause no loss of supercoiling (Snyder & Drlica, 1979; Manes et al., 1983) . The increase in supercoiling induced by coumermycin is accompanied by a transient 3-fold increase in gyrA expression (GyrB was not resolved by electrophoresis when cells were treated with coumermycin), and the increase in supercoiling is blocked by chloramphenicol (200pg/ml). We find no evidence that a reduction in supercoiling either precedes or accompanies the stimulation of gyrase expression. Low concentrations of oxolink acid (2 pg/ml) produce a transient 4-fold and 3-fold stimulation in the rate of expression of gyrA and gyrB respectively, but no change in supercoiling is detected in wild-type cells. Thus inhibitors of gyrase can stimulate gyrase expression when chromosomal supercoiling decreases (high coumermycin or oxolinic acid concentrations), remains unchanged (low oxolinic acid concentrations), or increases (low coumermycin concentration with wild-type strains or high oxolinic acid concentration with DM800 0x0').
The results described above are consistent with the homoeostatic model for gyrase regulation if the inhibitors exert a localized effect on supercoiling near the gyrase genes. Since there are about 50 topologically independent domains (Sinden & Pettijohn, 1981) , it is unlikely that a local effect would be detected by our measurements of average chromosomal supercoiling. We do not currently have sensitive methods to measure localized supercoiling.
Oxolinic acid as a probe for gyrase
Inhibitors specific for the gyrA gene product can also be used as probes for locating gyrase-DNA interactions. Oxolinic acid and related compounds appear to trap a gyrase-DNA reaction intermediate in which phospho-diesterase bonds of the DNA are broken and the DNA is covalently linked to gyrase (for review see Peebles et al., 1979) . When reaction mixtures containing gyrase, DNA and oxolinic acid are treated with alkali or an ionic detergent, DNA fragments are liberated. A similar phenomenon occurs in vivo: the DNA isolated from cells exposed to nalidixic or oxolinic acids is fragmented if the cell lysates are treated with alkali or ionic detergents. Since gyrA mutations that confer resistance to these drugs also prevent DNA cleavage, gyrase appears to be directly involved in this process. Thus mapping the positions of the DNA cleavages should provide information about the sites of gyrase action.
Measurement of DNA fragment size indicates that on average there are about the same number of chromosomal breaks induced by oxolinic acid (Snyder & Drlica, 1979) as there are topologically independent domains (Sinden & Pettijohn, 1981) . The availability of topoisomerase mutations having altered steady-state levels of supercoiling allowed us to ask if the distribution of gyrase correlates with supercoiling. We found that small changes in supercoiling (-25% or + 15%) have no measurable effect on the size of the DNA fragments generated by oxolinic acid (K. Drlica, G. Pruss, & S. Manes, unpublished work) . However, strains that have experienced a deletion of topA can exhibit an unusual response to the drug. There are approximately twice as many oxolinic acid-induced DNA cleavage events in strain DM800 as in a wild-type strain. With strain DM800 a small proportion of the cleavage events occur without the addition of an ionic detergent to cell lysates. Preliminary observations indicate that this altered cleavage behaviour depends on the presence of a gyrB compensatory mutation and an additional unidentified factor(s). These mutations are the only way we have found to change the size of the DNA fragments generated by oxolinic acid. It will be interesting to determine if the altered fragment size correlates with a change in the number of topologically independent domains in the chromosome.
Concluding remarks
The rapid progress in understanding the biochemistry of topoisomerases has provided a number of tools for studying the physiology of these enzymes and the role of intracellular supercoiling. Three anomalies involving gyrase inhibitors are pointed out above. First, chromosomal DNA relaxation is induced by oxolinic acid in a mutant in which topA is deleted. In vitro, oxolinic acid blocks the relaxing activity of gyrase (Gellert et al., 1977; . Thus it seems unlikely that either topoisomerase I or gyrase are responsible for this oxolinic acid-induced DNA relaxation. The source of this relaxation is unknown; perhaps it is topoisomerase I11 (Dean et al., 1983) . Second, inhibitors of gyrase increase expression from the gyrase genes regardless of the level of average chromosomal supercoiling. In vitro, expression from gyrase genes is higher if the DNA is relaxed (Menzel & Gellert, 1983) . Does this mean that superhelical tension in DNA around the gyrase genes can differ from the average levels or are other factors involved in the drug induction of gyrase? Third, under certain conditions inhibitors of gyrase can cause chromosomal supercoiling to increase. Increased supercoiling probably arises from stimulation of gyrase expression under conditions in which the enzyme retains some activity.
